Bone
Osteoporosis
Bone lost faster than expected for age, leaving fewer, thinner trabeculae; vertebrae collapse and hips and wrists fracture.
Causes et facteurs de risque
- Postmenopausal oestrogen deficiency, the commonest setting
- Age-related loss beyond the usual rate after the fourth decade
- Physical activity and good diet build and maintain bone mass
Aspect macroscopique
- Vertebral bodies with fewer, thinner trabeculae; compression fractures.
Au microscope
- Thin, sparse trabeculae of normal bone.
Évolution
- Peak bone mass is built in youth.
- After the fourth decade bone is lost; in osteoporosis, faster than usual.
- Weak trabecular bone fractures with little trauma: vertebrae, hip, wrist.
Complications
- Vertebral compression fractures
- Hip fractures: up to a third of elderly people with one may not survive a year
- Diagnosis by bone density (DEXA): a T-score below -2.5
Examens complémentaires
- DEXA bone densitometry
- A T-score of −2.5 or lower defines osteoporosis.
- Spine radiograph
- Reduced bone density and vertebral compression fractures.
- Blood tests
- Calcium, phosphate and alkaline phosphatase are normal; vitamin D, thyroid and other tests look for secondary causes.
Traitement médicamenteux
- Bisphosphonates: Pyrophosphate analogues that bind bone mineral and are taken up by osteoclasts, inhibiting bone resorption: the first-line drugs for osteoporosis, and used for bone metastases and hypercalcaemia.
- Denosumab (RANKL inhibitor): A monoclonal antibody against RANKL, the signal osteoclasts need to form and survive; a twice-yearly injection for osteoporosis, also used for bone metastases.
Médicaments à éviter ou à utiliser avec précaution
- Inhaled corticosteroids (ICS) (Avec précaution): High inhaled doses over years can reduce bone density.
- Proton pump inhibitors (PPIs) (Avec précaution): Long-term acid suppression is associated with fractures.
- Systemic corticosteroids (glucocorticoids) (Avec précaution): They reduce bone formation and calcium absorption: bone loss accelerates.
- Androgen deprivation therapy (GnRH analogues and antiandrogens) (Avec précaution): Removing testosterone accelerates bone loss.
- Aromatase inhibitors (Avec précaution): Removing the last oestrogen accelerates bone loss; bone density is checked and a bisphosphonate or denosumab added.
Anatomie concernée
Rédigé d’après
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 17, Bones, Joints, and Soft-Tissue Tumors, pp. 451, figs 17-10, 17-11
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.